经皮冠状动脉介入治疗术后应用泮托拉唑的临床效果观察

目的探讨泮托拉唑对经皮冠状动脉介入治疗(PCI)术后氯吡格雷抗血小板聚集和临床效果的影响。方法选取本院行PCI术的患者共92例,按随机原则将其分为治疗组和对照组,术前与术后均接受氯吡格雷及阿司匹林治疗,治疗组加用泮托拉唑。检测2组患者的血小板聚集率、血常规等指标,术后对患者进行随访。结果治疗组和对照组血小板聚集率分别为(29.93±10.48)%和(26.32±8.53)%,心肌缺血的发生率分别为8.7%和4.3%,2组间比较均无统计学差异,且均未发生严重的心血管以及出血等不良临床事件。结论泮托拉唑不会降低PCI术后氯吡格雷抗血小板聚集作用,不会增加临床心血管事件的发生率,同时能够明显降低消化道出血事件发生率。

Observation of therapeutic efficacy of pantoprazole after PCI procedure

Objective To explore the effect of pantoprazole on antiplatelet aggregation activity and clinical efficacy of clopidogrel after percutaneous coronary intervention(PCI).Methods A total of 92 PCI patients in our hospital were randomly divided into treatment and control groups.Both group received clopidogrel and aspirin therapy before and after surgery.The treatment group received additional pantoprazole.The platelet aggregation and blood routine indexes were detected in the two groups.The postoperative follow-up was conducted.Results The platelet aggregation rates in the treatment group and the control group were(29.93±10.48)% and(26.32±8.53)%,respectively.The incidence rates of myocardial ischemia were 8.7% and 4.3%,respectively.There was no statistically significant difference between the two groups.There were no serious adverse events such as cardiovascular event and bleeding.Conclusion Pantoprazole does not reduce the platelet aggregation activity of clopidogrel after PCI procedure and also does not increase the incidence of clinical cardiovascular events.At the same time it can significantly decrease the incidence of gastrointestinal bleeding.